Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 3 | 4 |
| 2007 | 4 | 5 | 9 |
| 2008 | 3 | 14 | 17 |
| 2009 | 5 | 3 | 8 |
| 2010 | 7 | 12 | 19 |
| 2011 | 7 | 7 | 14 |
| 2012 | 8 | 6 | 14 |
| 2013 | 8 | 14 | 22 |
| 2014 | 18 | 8 | 26 |
| 2015 | 16 | 5 | 21 |
| 2016 | 19 | 12 | 31 |
| 2017 | 15 | 15 | 30 |
| 2018 | 22 | 6 | 28 |
| 2019 | 14 | 12 | 26 |
| 2020 | 15 | 11 | 26 |
| 2021 | 22 | 13 | 35 |
| 2022 | 2 | 19 | 21 |
| 2023 | 3 | 18 | 21 |
| 2024 | 18 | 8 | 26 |
| 2025 | 26 | 10 | 36 |
| 2026 | 10 | 0 | 10 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials. Lancet Oncol. 2026 May; 27(5):592-603.
-
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study. Blood Adv. 2026 Apr 14; 10(7):2441-2451.
-
Nanoscale Direct-to-Biology Optimization of Cdk2 Inhibitors. J Med Chem. 2026 Apr 23; 69(8):9142-9162.
-
Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes. Leukemia. 2026 May; 40(5):946-954.
-
The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson's disease. Nat Aging. 2026 Mar; 6(3):626-635.
-
Nilotinib-Induced Retinal Artery Thrombosis in a Patient With Chronic Myeloid Leukaemia: A Rare Case. Cancer Rep (Hoboken). 2026 Feb; 9(2):e70501.
-
Fyn-Saracatinib Complex Structure Reveals an Active State-like Conformation. Int J Mol Sci. 2026 Jan 23; 27(3).
-
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge. Nat Commun. 2026 Jan 14; 17(1):1726.
-
Discovery and Characterization of a First-In-Class HCK/BTK PROTAC DFCI-002-06 for the Treatment of MYD88 Mutated B Cell Malignancies. J Med Chem. 2026 Jan 22; 69(2):1119-1134.
-
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia. Blood. 2026 Jan 01; 147(1):24-34.